Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Taxes (2018 - 2025)

Historic Change in Taxes for Ligand Pharmaceuticals (LGND) over the last 8 years, with Q3 2025 value amounting to -$864000.0.

  • Ligand Pharmaceuticals' Change in Taxes fell 10950.18% to -$864000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 17968.56%. This contributed to the annual value of -$2.3 million for FY2024, which is 22970.24% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Change in Taxes stood at -$864000.0, which was down 10950.18% from -$2.4 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Change in Taxes high stood at $12.0 million for Q1 2022, and its period low was -$16.7 million during Q4 2022.
  • Moreover, its 5-year median value for Change in Taxes was -$953000.0 (2024), whereas its average is -$92315.8.
  • Over the last 5 years, Ligand Pharmaceuticals' Change in Taxes had its largest YoY gain of 101875.0% in 2022, and its largest YoY loss of 30496.13% in 2022.
  • Ligand Pharmaceuticals' Change in Taxes (Quarter) stood at $8.1 million in 2021, then tumbled by 304.96% to -$16.7 million in 2022, then surged by 145.53% to $7.6 million in 2023, then tumbled by 138.39% to -$2.9 million in 2024, then soared by 70.38% to -$864000.0 in 2025.
  • Its Change in Taxes stands at -$864000.0 for Q3 2025, versus -$2.4 million for Q2 2025 and -$335000.0 for Q1 2025.